# Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

> **NCT05352893** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** 750 mg Imsidolimab
- **DRUG:** 300 mg Imsidolimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05352893
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-14
- **Primary completion:** 2023-08-17
- **Final completion:** 2023-08-17
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05352893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05352893, "Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05352893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*